



Pan drug-resistant *Acinetobacter baumannii* causing nosocomial infections among burnt children

Behnam Sobouti¹, Maryam Mirshekar^{2,3}, Shahrzad Fallah⁴, Aram Tabaei¹, Jalil Fallah Mehrabadi⁵, Atieh Darbandi^{*2,3}

Received: 4 Oct 2019

Published: 23 Mar 2020

Abstract

Background: Nosocomial infection caused by *Acinetobacter baumannii* has emerged as a world-wide serious problem in the emergence of multidrug-resistant (MDR). Infections caused by antibiotic-resistant strains of *A. baumannii* cannot be completely eliminated among the infected patients. This study aimed to monitor antibiotic resistance among *A. baumannii* strains isolated from burnt children.

Methods: After performing biochemical identification tests on 115 isolates, 62 were detected as *A. baumannii*. Minimum inhibitory concentration (MIC) was used to test susceptibility to colistin, and disk agar diffusion was used for the susceptibility of the isolates to the antibiotics Ciprofloxacin, Amikacin, Gentamicin, Cefepime, Meropenem, Imipenem, Ceftazidime, Levofloxacin and Piperacillin/Tazobactam. Bacterial species were isolated and identified as multidrug-resistant (MDR), extensively drug-resistant (XDR) and pan drug-resistant (PDR), based on the susceptibility patterns to elected antibiotics, deputing different classes of antimicrobial.

Results: The antibiotic susceptibility pattern out of a total of 62 bacterial strains used in this study. Thirty-six (58%) strains were categorized as MDR, 17 (27.5%) as XDR, and nine (14.5%) as PDR.

Conclusion: To reduce the threat of antimicrobial resistance, MDR, XDR and PDR *A. baumannii* strains must be evaluated by all clinical microbiology laboratories.

Keywords: PDR, *Acinetobacter baumannii*, Burnt Children

Conflicts of Interest: None declared

Funding: Iran University of Medical Science

*This work has been published under CC BY-NC-SA 1.0 license.

Copyright© Iran University of Medical Sciences

Cite this article as: Sobouti B, Mirshekar M, Fallah Sh, Tabaei A, Fallah Mehrabadi J, Darbandi A. Pan drug-resistant *Acinetobacter baumannii* causing nosocomial infections among burnt children y. *Med J Islam Repub Iran*. 2020 (23 Mar);34:24. <https://doi.org/10.47176/mjiri.34.24>

Introduction

Acinetobacter baumannii induced nosocomial infections, caught during hospitalization, have emerged as a serious worldwide problem, especially among immune-compromised, burnt and ICU (intensive care unit) patients (1). Multidrug resistance among the *hospital strains of this species has made it cumbersome, with immediate risk to the*

public health, to treat A. baumannii infections such as bacteremia, meningitis, pneumonia, and urinary tract infections (2).

MDR has been determined by European Center for Disease Prevention and Control (ECDC) and Center for Disease Control & Prevention (CDC) as the accumulated non-

Corresponding author: Dr Atieh Darbandi, darbandi.a@iums.ac.ir

1. Burn Research Center, Iran University of Medical Sciences, Tehran, Iran
2. Student Research Committee, Iran University of Medical Sciences, Tehran, Iran
3. Department of Microbiology, School of Medicine, Iran University of Medical Sciences Tehran, Iran
4. Shahid Beheshti University of Medical Sciences, Tehran, Iran
5. The Lister Laboratory of Microbiology, Tehran, Iran

↑What is “already known” in this topic:

Acinetobacter baumannii infections in burn patients may lead to a lag in wound healing, graft losses, and development of septicemia. Furthermore, prevalence caused by multidrug-resistant *A. baumannii* (MDRAB) is difficult to control and have fundamental morbidity and mortality, especially in the vulnerable hosts.

→What this article adds:

The current data indicated a high rate of resistance among *A. baumannii* isolates from burnt children. Since therapeutic options are limited for multidrug-resistant *A. baumannii* infections, finding new strategies for preventing healthcare-associated transmission of multidrug-resistant *A. baumannii* infections is urgent.

susceptibility to at minimum one factor in three or more antimicrobial classes (3). XDR has been specified as non-susceptibility to at minimum one factor in every but two or fewer antimicrobial classes (i.e., bacterial isolates subsist susceptible to only one or two antimicrobial classes). PDR has been specified as non-susceptibility to all factors in all antimicrobial classes (4). According to a previous study regarding the high prevalence of MDR, XDR and PDR strains of *A. baumannii* among Iranian patients (5), the current study was performed in order to monitor any increases in resistance among these isolates.

Methods

Clinical Sampling and Bacterial Identification

This short-term cross-sectional study was performed in Shahid Motahari Burns Hospital, Tehran, Iran from 15th April to 15th July 2016. Totally, 115 isolates were studied from burn wound infections of inpatients involved in burning with different burn levels and identified by conventional methods (Fig. 1). The tissue culture was performed based on previously confirmed protocol (5, 6).

Briefly, biopsy samples were collected by 3 mm punch tissue with a weight between 0.02 and 0.05 gram. In order to prevent tissue samples desiccation during transportation, the biopsy samples were then placed on a non-bacteriostatic moistened sterile gauze pad within a sterile container. The biopsy samples were cut into small pieces and homogenized by a homogenizer (BioMaster-Stomacher, Sewerd, England). The suspension was serially diluted and 0.1 cc sample was inoculated on 5% defibrinated sheep blood Columbia agar, Eosin Methylene Blue agar and Chocolate agar, and incubated at 37 °C for 24 hours. Standard microbiological tests in the laboratory were used to determine the isolates including Oxidase (negative), TSI (non-fermentative), Lysine decarboxylase (negative), lysine decarboxylase (positive), arginine hydrolase (positive), growth in 45 °C, Gelatin hydrolysis (positive), hydrolysis of esculin agar, reduction of nitrate, production of acid from glucose in OF media, hemolysis reaction on blood agar. Bacterial strains were preserved in Trypticase Soy Broth (TSB) with 20% Glycerol (7, 8).

Antibiotic Susceptibility Tests

The disk diffusion method was used in order to detect antimicrobial susceptibility in clinical isolates of *A. baumannii* conforming to the Clinical and Laboratory Standards Institute (CLSI 2018) instructions (9, 10). The following antibiotics disks from MAST Categories Ltd., Merseyside, UK, were used: Ciprofloxacin (CIP, 5 µg), Amikacin (AK, 30 µg), Gentamicin (GM, 10 µg), Cefepime (CPM, 30 µg), Meropenem (MEM, 10 µg), Imipenem (IMI, 10 µg), Ceftazidime (CAZ, 30 µg), Levofloxacin (LEV, 1 µg) and Piperacillin/Tazobactam (PTZ, 10 µg). Then, the determined *A. baumannii* isolates were tested for Colistin susceptibility by minimum inhibitory concentrations (MIC). *Pseudomonas aeruginosa* ATCC27853 and *Escherichia coli* ATCC 25922 were used as a control for the susceptibility tests.

First, *A. baumannii* strains were cultured on TSB and incubated at 37 °C for 24 hours. Subsequently, the turbidity of 0.5 McFarland standards was used as a standard method and the bacterial suspension was adjusted with it. The sterile swabs were plated on Mueller-Hinton agar (MH agar) and antibiotic disks were placed on the plate and incubated at 37 °C for 24 hours.

MDR and XDR in *A. baumannii* isolates were defined according to new standardized international document (11), by the results of antimicrobial susceptibility of *P. aeruginosa* to all antimicrobial agents listed in Table 1.

Antimicrobial susceptibility of colistin against *A. baumannii* isolates was investigated by the minimum inhibitory concentration (MIC) method. Colistin sulfate (Sigma-Aldrich, St. Louis, MO, USA) was tested over a range of dilutions (64-0.5µg/ml). For this purpose, 100 µl colistin sulfate (diluted in water) 128 mg/ml were added to 96-well U bottom microplates. In the following 10µl of bacterial suspension containing 1.5×10^5 CFU/ml of cells was added to wells with serially different concentrations of colistin. In the end, the microplate was incubated in ambient air at 37 °C for 24 h. The breakpoints of The Clinical and Laboratory Standards Institute (CLSI) were applied as references (12).



Fig. 1. A total of 115 isolates were studied during current survey in 2016 (The Medical Ethic Committee permitted us for releasing pictures)

Table 1. Antimicrobial drug categories and agent proposed for characterization of MDR, XDR and PDR in *A. baumannii* (7)

Antimicrobial categories	Multi-drug resistant (MDR)	Extensively-drug resistant(XDR)	Pan--drug resistant(PDR)
Definitions	Resistance to at least Three class of drug: 1) Cephalosporins 2) Fluroquinolons 3) Aminoglycoside	MDR Acinetobacter + Resistance to carbapenems	XDR Acinetobacter + Resistance to Polymyxins
Therapeutic Options	Carbapenems Polymyxins	Polymyxins Tigecycline	Combinations

Results

Sixty-two (54%) of bacterial isolates were distinguished as *A. baumannii* by means of standard microbiological tests in the laboratory. The mean age was 4.8 ± 3.5 years, including 34 (55%) males and 28 (45%) females. Two patients involved with PDR strains died (one male and one female).

According to antimicrobial susceptibility test, all isolates were resistant to ceftazidime (n=62, 100%), and then after ceftazidime, the most antibiotic resistance was related to ciprofloxacin (n=50, 81%). Least antibiotic resistance was related to levofloxacin (n=12, 19%). The rates of other antibiotic resistances are shown in [Chart 1](#).

Moreover, the rate of antibiotic resistance to colistin was determined using MIC and elucidated in [Table 2](#).

Consistent with definition of MDR, XDR and PDR strains (7), in this study, 36 (58%) out of 62 isolates were recognized as MDR, 17 isolates (27.5%) as XDR and nine (14.5%) isolates were as PDR among 62 clinical isolates of *A. baumannii* isolates from patients in Tehran, Iran.

Discussion

The presence of highly resistant bacteria, including MDR, XDR and PDR in hospitals, especially in intensive care units (ICU) and burn centers is a major threat to the treatment of patients worldwide. These bacteria are able to cause nosocomial infections and continue to impose serious challenges to clinicians' empirical and therapeutic decisions to treat burnt patients (13, 14).

Outbreaks of MDR, XDR and PDR strains of *A. baumannii* are currently reported worldwide. Custovic et al. treated 855 patients in Bosnia and isolated 54 *A. baumannii* strains from 105 nosocomial infections. With an incidence of 51.4% (54/105), it was the predominant cause of infection among the patients. Most of these strains were resistant to most antibiotics except tobramycin (87%; 47/54) and colistin (100%; 54/54) (2). Some of the antibiotic resistance percentages in Custovic's study were similar to those in our study. The resistance rates of *A. baumannii* strains respectively found in Custovic's and our study included piperacillin/tazobactam 98.1% (65%), ciprofloxacin 96.2% (80%), ceftazidime 94.4% (100%), cefepime 92.6% (50%), amikacin 92% (60%), meropenem 88.9% (50%) and gentamicin 60.4 % (70%). The percentages in brackets are related to our study.

Hojabri et al. collected 71 *A. baumannii* strains and analyzed them by reiterative extragenic palindromic PCR (rep-PCR), multi-locus sequence-based typing and an updated sequence group multiplex PCR. Sixty-seven (94.4%) out of the 71 isolates were resistant to at least three antibiotic classes and were considered as MDR. Sixty (84.5%) isolates were resistant together amikacin and carbapenems. About 65 (91.5%) were determined resistant to gentamicin and also 67 (94.4%) were resistant to both cefepime and ceftazidime (8). In contrast to our study which found PDR and XDR as well as MDR *A. baumannii* isolates, Hojabri only found MDR strains among the isolates. Another report




Chart 1. In vitro susceptibilities for 62 clinical isolates of pandrug-resistant *A. baumannii* (PDRAB) determined by disk diffusion [CAZ (Ceftazidime), CIP (Ciprofloxacin), GM (Gentamicin), TZP (Piperacillin/tazobactam), AK (Amikacin), FEP (Cefepime), MEP (Meropenem), LEV (Levofloxacin)]

Table 2. MIC value of colistin in the isolated *A. baumannii* PDR strains of Shahid Motahari Burn Hospital

MIC value	Killing activity				Total
	0.5	2	4	6	
No. of strains	0	0	7	2	9 (14.5 %)

from Iran (15) showed that out of the 60 *A. baumannii* isolates, 57 (95%) were MDR and 11.6% of the total strains were colistin-resistant (compared to 14.5% colistin-resistant in the current study). Moreover, results of the disk diffusion method showed that *A. baumannii* isolates had the highest resistance rate against gentamicin and ciprofloxacin (100% resistance) and the lowest resistance rate against imipenem (83% resistance). In our study, the resistance rates against gentamicin and ciprofloxacin were 70% and 80%, respectively.

In this study, out of the 115 clinical *A. baumannii* strains isolated from burnt children in Tehran, Iran, 36 (58 %) were recognized as MDR, 17 (27.5 %) as XDR and nine isolates (14.5%) as PDR. There are a few published pieces of literature reporting multidrug resistance among clinical isolates of *A. baumannii* in Iran and, to our knowledge, our study is the first report of such isolates among burnt children.

A more detailed study of molecular pathogenesis and mechanisms of antibiotics resistance among XDR and PDR strains is critical to overcoming challenges facing the treatment of such isolates. Furthermore, the discovery and development of new therapies and precise administration of the existing antimicrobial regimens based on antibiotics susceptibility tests will certainly reduce the high prevalence of resistant strains (16, 17).

Conclusion

The current data indicated a high rate of resistance among *Acinetobacter baumannii* isolates from burnt children. Since remedial choices are limited for multidrug-resistant *A. baumannii* infections, the finding and expansion of novel remedies, well-controlled administration of the antimicrobial diets, as well as a greater emphasis on strategies of preventing healthcare-associated transmission of multidrug-resistant *A. baumannii* infections are urgent.

Acknowledgments

The authors wish to extend their gratitude to Iran University of Medical Science for financial support and sponsorship.

Conflict of Interests

The authors declare that they have no competing interests.

References

1. Kouchak F, Askarian M. Nosocomial infections: the definition criteria. *Iran J Basic Med Sci.* 2012;37(2):72.
2. Sobouti B, Khosravi N, Daneshvar A, Fallah S, Moradi M, Ghavami Y. Prevalence of beta lactamase producing species of pseudomonas and acinetobacter in pediatric burn patients. *Ann Burns Fire Disasters.* 2015;28(3):171-77.
3. Hakyemez IN, Kucukbayrak A, Tas T, Yikilgan AB, Akkaya A, Yasayacak A, et al. Nosocomial *Acinetobacter baumannii* infections and changing antibiotic resistance. *Pak J Med Sci.* 2013;29(5):1245.
4. Enani MA. Antimicrobial resistance: insights from the declaration of world alliance against antibiotic resistance. *Saudi Med J.* 2015;36(1):11.
5. Kanungo R. Antimicrobial resistance: Action by laboratories today for a cure tomorrow. *Indian J Med Microbi.* 2011;29(3):205.
6. Magiorakos AP, Srinivasan A, Carey R, Carmeli Y, Falagas M, Giske C, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard

- definitions for acquired resistance. *Clin Microbiol Infect.* 2012;18(3):268-81.
7. Peleg AY, Seifert H, Paterson DL. *Acinetobacter baumannii*: emergence of a successful pathogen. *Clin Microbiol Rev.* 2008;21(3):538-82.
8. Peleg AY, de Brey A, Adams MD, Cerqueira GM, Mocali S, Galardini M, et al. The success of *Acinetobacter* species: genetic, metabolic and virulence attributes. *PLoS One.* 2012;7(10):e46984.
9. Kallstrom G. Are quantitative bacterial wound cultures useful? *J Clin Microbiol.* 2014;52(8):2753-6.
10. Bauer A, Kirby W, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. *Am J Clin Pathol.* 1966;45(4_ts):493-6.
11. Mirshekar M, Shahcheraghi F, Azizi O, Solgi H, Badmasti F. Diversity of class I integrons, and disruption of *carO* and *dacD* by insertion sequences among *Acinetobacter baumannii* isolates in Tehran, Iran. *Microb Drug Resist.* 2018;24(4):359-66.
12. Hojabri Z, Pajand O, Bonura C, Aleo A, Giammanco A, Mamma C. Molecular epidemiology of *Acinetobacter baumannii* in Iran: endemic and epidemic spread of multiresistant isolates. *J Antimicrob Chemother.* 2014;69(9):2383-7.
13. Maslow JN, Glaze T, Adams P, Lataillade M. Concurrent outbreak of multidrug-resistant and susceptible subclones of *Acinetobacter baumannii* affecting different wards of a single hospital. *Infect Control Hosp Epidemiol.* 2005;26(1):69-75.
14. Bialvaei AZ, Kouhsari E, Salehi-Abargouei A, Amirzofari N, Ramazanzadeh R, Ghadimi-Daresajini A, et al. Epidemiology of multidrug-resistant *Acinetobacter baumannii* strains in Iran: a systematic review and meta-analysis. *J Chemother.* 2017;29(6):327-37.
15. Vakili B, Fazeli H, Shoaie P, Yaran M, Ataei B, Khorvash F, et al. Detection of colistin sensitivity in clinical isolates of *Acinetobacter baumannii* in Iran. *J Res Med Sci.* 2014;19(Suppl 1):S67.
16. Eliopoulos GM, Maragakis LL, Perl TM. *Acinetobacter baumannii*: epidemiology, antimicrobial resistance, and treatment options. *Clin Infect Dis.* 2008;46(8):1254-63.
17. McArthur AG, Waglechner N, Nizam F, Yan A, Azad MA, Baylay AJ, et al. The comprehensive antibiotic resistance database. *Antimicrob Agents Chemother.* 2013;57(7):3348-57.